3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Leukemia
2
Tuberous Sclerosis
1
Tourette Syndrome
1
Tic Disorders
1
Preleukemia
1
Neurodevelopmental Disorders
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Hematologic Diseases
1
Glioblastoma
1
Fragile X Syndrome
1
DiGeorge Syndrome
1
Depression
1
Cytopenia
1
Bone Marrow Diseases
1
Autistic Disorder
1
Autism Spectrum Disorder
1
Attention Deficit Disorder with Hyperactivity
1
Anxiety Disorders
1
Anemia
1
22q11 Deletion Syndrome
1
Interventions
Imatinib Mesylate
5
ruxolitinib
4
ponatinib
4
nilotinib
4
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
4
Azacitidine
3
fludarabine phosphate
2
fludarabine
2
Whole-Body Irradiation
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Cyclophosphamide
2
Busulfan
2
spartalizumab
1
sonidegib
1
simtuzumab
1
sabatolimab
1
pembrolizumab
1
ibrutinib
1
bosutinib
1
Zoledronic Acid
1
Sertraline
1
SCIO-469
1
Quality of Life
1
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
1
Lenalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Bone Marrow Diseases
×
Sertraline
×
Clear all
NCT02452983
2022-06-02
SS1
Baylor College of Medicine
Phase 1
Terminated
14 enrolled